Skip to main content
Medica logo

Medica — Investor Relations & Filings

Ticker · MDC ISIN · IT0005460149 LEI · 815600FE16FA9F3E2296 XMIL Manufacturing
Open in API
Filings indexed 114 across all filing types
Latest filing 2022-09-01 M&A Activity
Country IT Italy
Listing XMIL MDC

About Medica

https://www.medica.it/

Medica S.p.A. is a company specializing in advanced purification technologies. Its core business is the development and production of products for blood purification, with applications in dialysis, Continuous Renal Replacement Therapy (CRRT), and apheresis. The company's medical product portfolio includes polysulfone membranes, dialysis filters, hemofilters, and blood lines. It has expanded its expertise into other medical fields such as cardiology, oncology surgery, organ transplantation, urology, and gastroenterology. Leveraging its filtration know-how, Medica also operates a water purification division that produces hollow fiber membranes. Additionally, the company offers turnkey solutions for the biomedical sector, providing vertically integrated services from research and development to manufacturing, industrial automation, and regulatory management.

Recent filings

Filing Released Lang Actions
Medica acquisisce il 100% di Slom Srl
M&A Activity Classification · 99% confidence The document is a press release dated September 1, 2022, announcing that Medica S.p.A. acquired 100% of Slom Srl. This transaction involves financing, capital structure changes (acquisition), and is a significant corporate event. It details the rationale, financial summary of the acquired company, and the transaction terms (price, financing method). This type of announcement, detailing a merger or acquisition activity, aligns best with the 'M&A Activity' category (TAR). It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a general regulatory announcement (RNS), but a specific corporate action disclosure.
2022-09-01 Italian
Medica SpA - Preliminary consolidated Net Revenues and Net Financial Position as of 30 June 2022
Earnings Release Classification · 98% confidence The document is explicitly labeled as a "Press release" and provides preliminary consolidated financial results for the first half of 2022 (ending June 30, 2022), including revenues (€ 20.4 million) and net financial position (€ 8.8 million). It also mentions that the full consolidated half-year report will be approved on September 28, 2022. This structure—a brief, high-level announcement of period results via press release, preceding the formal filing of the comprehensive report—is characteristic of an Earnings Release (ER). It is not the full Interim Report (IR) itself, as it states the data is preliminary and the formal report is pending audit/approval. H1 2022
2022-08-05 Italian
Medica SpA - Ricavi Netti e Posizione Finanziaria Netta preconsuntivi consolidati al 30 giugno 2022
Earnings Release Classification · 98% confidence The document is explicitly labeled as a "Comunicato stampa" (Press Release) in Italian. It reports preliminary consolidated revenue and net financial position figures for the first half of 2022 (H1 2022), dated August 5, 2022. It highlights key financial metrics and business segment performance for the period. This content structure—a brief announcement of period-end financial results—is characteristic of an Earnings Release (ER). Although it mentions that the full 'relazione semestrale consolidata' (consolidated semi-annual report) will be approved later (September 28, 2022), this document itself is the initial release of the results, fitting the definition of an Earnings Release (ER). It is too detailed for a simple Report Publication Announcement (RPA) and is not the comprehensive report itself (which would be an IR). H1 2022
2022-08-05 Italian
Medica SpA acquires 51% of Spindial SpA
M&A Activity Classification · 99% confidence The document is a press release dated July 21, 2022, announcing that Medica S.p.A. has acquired 51% of Spindial S.p.A. This announcement details a significant corporate transaction, specifically a merger or acquisition activity (M&A). Based on the provided definitions, the category 'M&A Activity (Code: TAR)' is the most appropriate fit for documents detailing merger proposals or takeover bids, which includes acquisitions.
2022-07-21 English
Medica SpA acquisisce il 51% di Spindial SpA
M&A Activity Classification · 99% confidence The document text is an official press release dated July 21, 2022, announcing that Medica S.p.A. has acquired a 51% stake in Spindial S.p.A. This announcement details the strategic rationale, financial figures of the acquired company (revenues and EBITDA for 2021), the transaction structure (purchase price, financing), and management continuity. This type of announcement, detailing a significant corporate transaction like an acquisition, falls under the category of Capital/Financing Update (CAP) or potentially a general Regulatory Filing (RNS) if no other category fits perfectly. Since it explicitly details a financing/capital structure change (acquisition of equity stake), 'CAP' is the most specific fit among the provided options, as it relates to capital structure changes and fundraising activities, even though it's an M&A event. However, given the strong focus on the acquisition itself, 'TAR' (M&A Activity) is also highly relevant. Since the definitions for TAR are 'merger proposals or takeover bids' and this is a completed acquisition announcement, 'CAP' (Capital/Financing Update) which covers 'company fundraising, financing activities, or capital structure changes' is a strong candidate. Given the context of corporate actions, M&A activity (TAR) is often the primary classification for acquisitions. I will select TAR as the primary classification for a completed acquisition announcement.
2022-07-21 Italian
Medica SpA to the event Euronext Growth Milan Conference 2022
Regulatory Filings Classification · 100% confidence The document is a press release dated May 17, 2022, announcing that MEDICA S.p.A. will be attending the 'Euronext Growth Milan Conference 2022' on May 25, 2022. It specifies which executives will meet investors and explicitly states: 'The documentation dedicated to the investors is available for consultation on the website www.medica.it, section "Investors".' This structure—an announcement about an upcoming investor event where documentation will be presented or made available—is characteristic of an Investor Presentation (IP) or a general announcement about investor relations activities. Since the document itself is an announcement about an event where investor materials are involved, and it is short (under 5,000 characters), it strongly suggests it is either an announcement of an upcoming presentation or a brief update related to investor engagement. Given the context of meeting investors at a conference, the most fitting category is Investor Presentation (IP), as this release serves to inform the market about the company's engagement with investors, often preceding or accompanying the actual presentation materials. It is not the presentation itself, but it is directly related to investor engagement materials.
2022-05-17 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.